Showing 42,461 - 42,480 results of 133,317 for search '(( 2 c decrease ) OR ( 5 ((((step decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 2.41s Refine Results
  1. 42461

    Data_Sheet_3_Global Burden Attributable to High Low-Density Lipoprotein-Cholesterol From 1990 to 2019.docx by Heyue Du (11229207)

    Published 2022
    “…We applied the weighted segmented regression with break-point estimation to detect the linear piecewise relationship between SDI and high LDL-C disease burden.</p>Results<p>Globally, 3.00 million (95% uncertainty interval [UI], 2.35–3.76 million) people in 1990 and 4.40 million (95% UI, 3.30–5.65 million) people died from high LDL-C in 2019. …”
  2. 42462

    Data_Sheet_1_Global Burden Attributable to High Low-Density Lipoprotein-Cholesterol From 1990 to 2019.docx by Heyue Du (11229207)

    Published 2022
    “…We applied the weighted segmented regression with break-point estimation to detect the linear piecewise relationship between SDI and high LDL-C disease burden.</p>Results<p>Globally, 3.00 million (95% uncertainty interval [UI], 2.35–3.76 million) people in 1990 and 4.40 million (95% UI, 3.30–5.65 million) people died from high LDL-C in 2019. …”
  3. 42463
  4. 42464

    Proliferation of NG2+ cells in response to systemic lipopolysaccharide treatment. by Malin Wennström (289876)

    Published 2014
    “…In contrast, a significant decreased number of NG2+/ki67+ cells were detected in the BL (B), the Hilus (C) and the ML (D), but not in the mPFC (A), 24 h after LPS treatment compared to saline treatment. …”
  5. 42465

    Characteristics of the included literature. by Wenpin Cai (13779001)

    Published 2024
    “…The relative abundance of <i>Ruminococcus</i>, <i>Faecalibacterium</i>, and <i>Coprococcus</i> all decreased, with total SMDs of -0.96 (95% CI -1.29 to -0.63, I<sup>2</sup> = 4.8%), -1.13 (95% CI -2.07 to -0.19, I<sup>2</sup> = 80.5%), and -1.66 (95% CI -3.04 to -0.28, I<sup>2</sup> = 91.5%). …”
  6. 42466

    PRISMA flow diagram. by Wenpin Cai (13779001)

    Published 2024
    “…The relative abundance of <i>Ruminococcus</i>, <i>Faecalibacterium</i>, and <i>Coprococcus</i> all decreased, with total SMDs of -0.96 (95% CI -1.29 to -0.63, I<sup>2</sup> = 4.8%), -1.13 (95% CI -2.07 to -0.19, I<sup>2</sup> = 80.5%), and -1.66 (95% CI -3.04 to -0.28, I<sup>2</sup> = 91.5%). …”
  7. 42467
  8. 42468
  9. 42469
  10. 42470

    Table_2_Lenalidomide potentially reduced the level of cell- associated HIV RNA and improved persistent inflammation in patients with HIV-associated cryptococcal meningitis a pilot... by Xiang Liu (119470)

    Published 2022
    “…</p>Methods<p>Lenalidomide was administered orally for 48 weeks to patients with HIV-associated cryptococcal meningitis (HIV-CM). A HIV-1 latency model was treated with or without lenalidomide ex vivo for 5 days. …”
  11. 42471

    <i>SmoA1</i> +; <i>Pten</i> +/− medulloblastomas down-regulate expression of targets of <i>sonic hedgehog</i> (<i>Shh</i>) signaling. by Robert C. Castellino (248365)

    Published 2010
    “…Relative expression of <i>Gli1</i>, <i>Gli2</i>, <i>N-myc</i>, and <i>cyclin-D1</i> was decreased 5.6, 7.6, 4.3, and 2.8-fold (<b>*</b>, p<0.05 for all transcripts), respectively in <i>SmoA1</i> +; <i>Pten</i> +/− (white bars) medulloblastomas. …”
  12. 42472

    Representation of 2 different disease courses in 19 DMD patients stratified into 2 groups, in which a 24-month follow-up was available according to the results obtained from linear... by Chiara Marchesi (377705)

    Published 2013
    “…In the second group, the MRC% decreased by approximately 25%. In a subgroup including 4 DMD patients of the first group and in 5 DMD patients of the second group, we measured CD133+CXCR4+CD34- cells levels. …”
  13. 42473

    MCPIP1 ribonuclease can bind and cleave <i>AURKA</i> mRNA in <i>MYCN</i>-amplified neuroblastoma cells by Iwona Nowak (9283821)

    Published 2021
    “…We showed that the levels of several transcripts involved in cell cycle progression decreased in BE(2)-C and KELLY cells overexpressing MCPIP1 in a ribonucleolytic activity-dependent manner. …”
  14. 42474

    Social support, social network size, social strain, stressful life events and CHD in women with type 2 diabetes – a cohort study based on the Women’s Health Initiative by Junmei Miao Jonasson (8769815)

    Published 2020
    “…</p> <p><b> </b></p> <p><b>Research Design and Methods</b></p> <p>From the Women’s Health Initiative, 5,262 postmenopausal women with type 2 diabetes at baseline were included. …”
  15. 42475
  16. 42476

    Data_Sheet_1_Lipid-lowering drug targets and Parkinson's disease: A sex-specific Mendelian randomization study.docx by Yangfan Zhao (13565389)

    Published 2022
    “…Modifiable risk factors have been explored as possible options for decreasing risk or developing drug targets to treat PD, including low-density lipoprotein cholesterol (LDL-C). …”
  17. 42477

    Comparison of PfRH1 expression in merozoite of W2mef and W2mef (switched). by Xiaohong Gao (50514)

    Published 2008
    “…<p>(A) Invasion inhibition assay of W2mef and W2mef (switched) with αrRII-3 and αrtRVIII, including pre-immune serum in 1∶10 to 1∶2560 dilutions. …”
  18. 42478

    Image_5_Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.jpeg by Carmen Mestre-Durán (7121327)

    Published 2023
    “…Only the highest doses of ruxolitinib led to a decrease in the pro-inflammatory cytokines tumor necrosis factor α, interferon-γ, interleukin-6, and interleukin-1β. …”
  19. 42479

    QBP1 interferes with Orb2 amyloid formation in vitro. by Rubén Hervás (161905)

    Published 2016
    “…<b>(B)</b> QBP1 but not SCR drastically reduced the turbidity at 405 nm of aged Orb2A PLD. <b>(C)</b> QBP1 reduces the quantity of amyloid formed as shown by measuring the CR bound to Orb2A PLD. …”
  20. 42480

    NGS analysis of OA vs OCD equine plasma. by Joshua Antunes (18017945)

    Published 2024
    “…Towards red indicates a fold increase; towards blue represents a fold decrease; c) Pathway analysis using miRPath v.3 and Tarbase v7.0 assessing derived interactions and indicated pathways to have predicted interactions with miRNAs identified to be differentially expressed.…”